Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis

NEW YORK, April 3, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Nordion Inc. (NYSE: NDZ), Intuitive Surgical, Inc. (NASDAQ: ISRG), and Novartis AG (NYSE: NVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Gilead Sciences Inc. Analyst Notes 

On March 28, 2014, Gilead Sciences Inc. (Gilead) announced a settlement method for its conversion obligations related to any 1.00% Senior Convertible Notes due 2014 (Notes) submitted for conversion on or after February 1, 2014 entirely in cash. In accordance with the foregoing, Gilead informed Wells Fargo Bank, National Association, the Trustee for the Notes, that it had designated a "Cash Percentage" (as defined in the indenture governing the Notes (Indenture) of 100% to apply to the "Daily Share Amount" for every "Trading Day" during the relevant "Conversion Reference Period" (each as defined in the Indenture) applicable to the Notes. The full analyst notes on Gilead Sciences Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/GILD/report.pdf

--

Pfizer Inc. Analyst Notes 

On March 28, 2014, Pfizer Inc. (Pfizer) reported that US Food and Drug Administration (FDA) has approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing  broader access to a brand, both, doctors and patients have trusted for years for people suffering from frequent heartburn. The Company stated that it has acquired exclusive global rights from AstraZeneca to market non-prescription Nexium® in 2012. Commenting on the drug approval, Paul Sturman, President, Pfizer Consumer Healthcare, said, "Switching medicines, whenever appropriate, from prescription to non-prescription status improves access, empowers consumers to care for their own health and is an important strategy for Pfizer. The FDA approval of Nexium® 24HR is a significant milestone in executing against our plan." The full analyst notes on Pfizer Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/PFE/report.pdf

--

Nordion Inc. Analyst Notes 

On March 31, 2014, shares of Nordion Inc. (Nordion) skyrocketed 10.66% to end the trading session at $11.52 on record high volumes; a day after Nordion signed an agreement with Sterigenics, in which the latter has agreed to acquire the former for $11.75 per share in cash.  On March 28, 2014, Nordion announced that it has entered into a definitive agreement with Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA, to be acquired in a transaction valued at nearly $727 million. After the acquisition, Nordion will operate as a standalone company within Sterigenics and will continue to operate under the Nordion name. The acquisition will be funded using a combination of new debt facilities and equity financing, both of which are fully committed, Sterigenics' cash on hand, and a portion of Nordion's cash on hand. The transaction has been unanimously approved by the Board of Directors of Nordion. The full analyst notes on Nordion Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/NDZ/report.pdf

--

Intuitive Surgical, Inc. Analyst Notes 

On March 31, 2014, shares of Intuitive Surgical, Inc.'s (Intuitive Surgical), a global leader in robotic-assisted, minimally invasive surgery, surged 0.69%, closing the trading session at $437.99. During the session, the Company's shares opened at $434.98 and oscillated in the range of $433.00 - $442.00. A total of 0.52 million shares were traded during the day, significantly higher than its 30-day average trading volume of 0.37 million shares. Over the previous three trading sessions, the shares of the Company increased 3.14%, as compared to the NASDAQ Composite which moved 0.61% higher during the same period. The full analyst notes on Intuitive Surgical, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04032014/ISRG/report.pdf

--

Novartis AG Analyst Notes 

On March 31, 2014, Novartis AG (Novartis) reported that the Data Monitoring Committee (DMC) unanimously recommended early closure of the PARADIGM-HF study, a randomized, double-blind, Phase III outcome study evaluating the efficacy and safety profile of LCZ696 versus enalapril (a widely used ACE inhibitor) in 8,436 patients with heart failure with reduced ejection fraction. The study indicated that patients with chronic heart failure with reduced ejection fraction (HF-REF) who received LCZ696 lived longer without being hospitalized for heart failure than those who received standard care with ACE-inhibitor enalapril. However, based on the compelling efficacy and primary endpoint having been met, the trial will now close early. The Company informed that the results of PARADIGM-HF will be submitted to a major medical conference for presentation and it will also initiate discussions with global health authorities regarding approval for marketing. The full analyst notes on Novartis AG are available to download free of charge at:

http://www.AnalystsReview.com/04032014/NVS/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review